24/7 Market News Snapshot 03 September, 2025 – BIOMERICA INC (NASDAQ:BMRA)

September 3, 2025

DENVER, Colo., 03 September, 2025 (www.247marketnews.com) – (NASDAQ:BMRA) are discussed in this article.
Biomerica Inc. (BMRA) is currently experiencing a significant surge in market activity, with its stock price reaching $3.208 in pre-market trading, marking a robust increase of approximately 6.93% from the previous close of $3.000. This notable rise in share price is accompanied by a trading volume of 3.77 million shares, reflecting heightened investor interest and positive market sentiment surrounding the company. Investors and traders are advised to keep an eye on key support levels near the previous closing price, as well as resistance points around $3.25, which could indicate future price movements.

In addition to its stock performance, Biomerica is proud to announce the recent approval of its Fortel® Kidney Test for home use by the Ministry of Health and Prevention. This pivotal milestone is aimed at improving access to crucial health diagnostics, particularly for early detection of kidney damage in high-risk populations such as individuals with diabetes and hypertension. The Fortel® Kidney Test is designed to yield results within ten minutes, efficiently identifying low levels of albumin in urine, an early marker for kidney disease.

Given the global rise in chronic kidney disease (CKD), driven largely by the increasing prevalence of diabetes and hypertension, the introduction of the Fortel® test is a timely intervention that could facilitate early medical action, mitigating the risks associated with CKD. Zack Irani, CEO of Biomerica, emphasized the test’s role in preventive healthcare, stating that it effectively addresses a critical gap by enabling early detection.

With plans to make the Fortel® Kidney Test available through pharmacies, clinics, and hospitals, Biomerica reinforces its commitment to advancing healthcare solutions. This strategic initiative aligns with global efforts to combat the rising incidence of CKD, enhancing patient outcomes and empowering healthcare providers with innovative diagnostic tools.

Related news for (BMRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.